Showing 7031-7040 of 8077 results for "".
- Residents of Distinction Attend 2018 Coastal Dermatology Symposiumhttps://practicaldermatology.com/news/residents-of-distinction-attend-2018-coastal-dermatology-symposium/2457554/As part of the dermMentors Resident of Distinction Award program, sponsored by Beiersdorf Inc., five dermatology residents attended the 14th Annual Coastal Dermatology Symposium, held in Monterey, CA October 3-6, 2018. The 2018 dermMentors™
- Real-world Evaluation Study Confirms Benefits of ARTAS iX Robotic Hair Restoration Systemhttps://practicaldermatology.com/news/real-world-evaluation-study-confirms-benefits-of-artas-ix-robotic-hair-restoration-system/2457560/Restoration Robotics, Inc. (NASDAQ: HAIR), the global leader in robotic hair restoration, today announced results from a real-world evaluation study. The new ARTAS iX™ Robotic Hair Restoration System demonstrates clinical efficiency in hair harvesting and implanta
- Psoriasis Plus Hypertension Equals Greater Need for Heart Surgeryhttps://practicaldermatology.com/news/psoriasis-plus-hypertension-equals-greater-need-for-cardiovascular-interventions/2457559/Patients with psoriasis and hypertension need more cardiovascular procedures and surgeries than hypertensive patients without psoriasis, a new study in the Journal of Dermatology suggests. In 5.62 year
- Aclaris Acquires Rhofade from Allerganhttps://practicaldermatology.com/news/aclaris-acquires-rhofade-from-allergan/2457561/Aclaris Therapeutics, Inc. has entered into a definitive asset purchase agreement with Allergan Sales, LLC to acquire worldwide rights to Rhofade® (oxymetazoline hydrochloride) cream, 1% and additional intellectual property. The acquisition includes an exclusive license to certain intel
- Lumenis Introduces SPLENDOR X, New Laser Hair Removal Solutionhttps://practicaldermatology.com/news/lumenis-introduces-splendor-x-new-laser-hair-removal-solution/2457563/Lumenis Ltd. has launched SPLENDOR X, the first solid state laser system equipped with the unique BLEND X technology for fast and effective hair removal and skin solutions. The technology was showcased for the first time at the 2018 American Society of Dermatological Surgery (ASDS) in Phoenix thi
- Pre-conditioning Added to Sebacia Microparticles Enhances Outcomeshttps://practicaldermatology.com/news/pre-conditioning-added-to-sebacia-microparticles-enhances-outcomes/2457567/Using pre-conditioning in conjunction with Sebacia Microparticles for treatment of acne leads to enhanced outcomes, new data suggest. In fact, results from a real-world, pre-conditioning registry trial in Europe demonstrate that the combination of pre-conditioning followed by Sebacia Mi
- Cellulite Reduction Seen With Cellfina Lasts Five Yearshttps://practicaldermatology.com/news/cellulite-reduction-seen-with-cellfina-lasts-five-years/2457566/One Cellfina treatment improves the appearance of cellulite on the thighs and buttocks for five years, according to new data presented by Merz at the Annual Meeting of the American Society for Dermatologic Surgery (ASDS) in Phoenix, AZ. This new data b
- Endo Presents Data on the Perception and Measurement of Cellulite Severity at ASDS Meetinghttps://practicaldermatology.com/news/endo-presents-data-on-the-perception-and-measurement-of-cellulite-severity-at-asds-meeting/2457568/The new Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) is a reliable tool for evaluating cellulite severity of the buttocks and thighs and correlates well with the Patient Reported Photonumeric Cellulite Severity Scale, according to research presented by
- Galderma Ups Its Aesthetic R&D Gamehttps://practicaldermatology.com/news/galderma-ups-their-aesthetic-r-d-game/2457570/Galderma Laboratories, L.P. is initiating six new Phase III and IV U.S. aesthetic clinical trials. The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology products; two studies for Dysport evaluating patient satisfaction and
- AlmirallShare Issues Call for Proposalshttps://practicaldermatology.com/news/almirallshare-issues-call-for-proposals/2457571/Almirall is seeking to find novel targets and concepts in the treatment of dermatological diseases. The company’s AlmirallShare open innovation platform is calling for proposals from October 10, 2018 to February 28, 2019 from universities, research centers, start-ups, biotechs and phar